1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Spotlight On Sarepta Post-BioMarin Duchenne Rejection

 
• By Donna Young

It was highly likely the FDA was going to turn down BioMarin Pharmaceutical Inc. on its Duchenne muscular dystrophy (DMD) drug Kyndrisa (drisapersen), given the beating it took this past November at the meeting of the agency's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee and the fact regulators had earlier called the firm's data "inconsistent," and in some cases, "contradictory."

It was highly likely the FDA was going to turn down BioMarin Pharmaceutical Inc. on its Duchenne muscular dystrophy (DMD) drug Kyndrisa (drisapersen), given the beating it took this past November at the meeting of the agency's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee and the fact regulators had earlier called the firm's data "inconsistent," and in some cases, "contradictory."

BioMarin investors were prepared for the bad news, and at first blush, even pushed shares of the company up 3.2%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

More from Therapy Areas